Abiopharma

🔍 SCHAEFFER DAVE (Executive)

Company: COGENT COMMUNICATIONS HOLDINGS, INC. (CCOI)

Report Date: 2026-04-01

Detailed Transactions and Holdings:

• Sold 58,667 shares of common stock (Direct)
  Date: 2026-04-01 | Code: D | equity_swap_involved: 0 | shares_owned_after: 638,476.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 29,333 shares of common stock (Direct)
  Date: 2026-04-01 | Code: G | equity_swap_involved: 0 | shares_owned_after: 609,143.00 | transaction_form_type: 4 | Footnotes: F3
• Acquired 29,333 shares of common stock (Direct)
  Date: 2026-04-01 | Code: G | equity_swap_involved: 0 | shares_owned_after: 258,990.00 | transaction_form_type: 4 | Footnotes: F3

Footnotes:

• F1: 1. On January 3, 2022, the reporting person was granted an award of up to 88,000 performance shares. Tranche 1 of the award consisted of 29,333 shares based on the Company's organic growth rate in revenue as compared to 1.5 times the organic growth rate of the NASDAQ Telecommunications Index ("NTI") between January 1, 2022, and December 31, 2025. Tranche 2 of the award consisted of 29,333 shares based on the Company's organic growth rate in cash flows from operating activities as compared to 2.0 times the organic growth rate of the NTI between January 1, 2022, and December 31, 2025. Tranche 3 of the award consisted of 29,334 shares based on the Company's total shareholder return as compared to the total shareholder return of the NTI between January 1, 2022, and December 31, 2025.
• F2: 2. On April 1, 2026, the Company determined that the performance criteria for the Tranche 1 had been achieved and 29,333 shares of common stock were earned and vested. The Company also determined that the performance criteria for Tranches 2 and 3 had not been achieved and that 58,667 shares were therefore forfeited.
• F3: 3. These shares were transferred to a family trust for no consideration.